Search Results 131-140 of 17241 for fibrosis quistica
... Fibrosis (IPF). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health ...
Growing up, Dylan Randazzo, 25, faced many struggles after being diagnosed with cystic fibrosis at birth. “I was always sick,” says the New York native of ...
“Individuals with idiopathic pulmonary fibrosis express difficulty completing routine activities. There are currently no effective treatment options, and the ...
The purpose of this study is to evaluate an ultrasound technology that may be used to evaluate liver fibrosis. Participation eligibility. Participant ...
Safety and Efficacy of Simtuzumab (GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH) · Overview.
Clinical Trials · A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) · More about research at Mayo ...
A Study Of Inhaled RVT-1601 For The Treatment Of Persistent Cough In Idiopathic Pulmonary Fibrosis (IPF) · Overview · Participation eligibility · Participating ...
The primary purpose of this study is to evaluate the effectiveness of BG00011 compared with placebo in participants with Idiopathic Pulmonary Fibrosis (IPF).
A Study of a Computer-Aided Analysis Tool for the Assessment of Pulmonary Fibrosis Treatment · Overview · Participation eligibility · Participating Mayo Clinic ...
They compared the outcomes of 1,255 treated (with either medication) and 1,255 untreated adults with idiopathic pulmonary fibrosis. The untreated group members ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!